Copy number variant hotspots in Han Taiwanese population induced pluripotent stem cell lines - lessons from establishing the Taiwan human disease iPSC Consortium Bank

Abstract

Background: The Taiwan Human Disease iPSC Service Consortium was established to accelerate Taiwan's growing stem cell research initiatives and provide a platform for researchers interested in utilizing induced pluripotent stem cell (iPSC) technology. The consortium has generated and characterized 83 iPSC lines: 11 normal and 72 disease iPSC lines covering 21 different diseases, several of which are of high incidence in Taiwan. Whether there are any reprogramming-induced recurrent copy number variant (CNV) hotspots in iPSCs is still largely unknown. Methods: We performed genome-wide copy number variant screening of 83 Han Taiwanese iPSC lines and compared them with 1093 control subjects using an Affymetrix genome-wide human SNP array. Results: In the iPSCs, we identified ten specific CNV loci and seven "polymorphic" CNV regions that are associated with the reprogramming process. Additionally, we established several differentiation protocols for our iPSC lines. We demonstrated that our iPSC-derived cardiomyocytes respond to pharmacological agents and were successfully engrafted into the mouse myocardium demonstrating their potential application in cell therapy. Conclusions: The CNV hotspots induced by cell reprogramming have successfully been identified in the current study. This finding may be used as a reference index for evaluating iPSC quality for future clinical applications. Our aim was to establish a national iPSC resource center generating iPSCs, made available to researchers, to benefit the stem cell community in Taiwan and throughout the world.

Cardio- and Neurotoxicity of Selected Anti-COVID-19 Drugs

“…Immunocytochemistry was performed as previously described [44]. Briefly, cells were fixed in 4% paraformaldehyde, and then permeabilized using 0.1% Triton-X100 when required.…”

Opportunities and Challenges of Human IPSC Technology in Kidney Disease Research

“…With the improved reprogramming methods, various human cell types have been successfully applied to generate iPSCs. These include fibroblasts, peripheral blood mononuclear cells (PBMCs), T cells, B cells, hepatocytes, cord blood, dental pulp, skin, cardiomyocytes, and other somatic cells [ 18 , 20 ]. Theoretically, all cells in the human body have the potential to be reprogrammed to iPSCs.…”

“…Theoretically, all cells in the human body have the potential to be reprogrammed to iPSCs. With the advantages of being least invasive and easy to assess, PBMCs have become the most common cell source for human iPSC generation in biobanks [ 18 , 19 , 20 , 21 , 22 , 23 , 24 ].…”

“…Several national or cross-institutional initiatives have established iPSC biobanks to generate, deposit, and deliver high-quality iPSCs for researchers or for therapeutic applications [ 18 , 20 , 22 ]. For example, the iPS Cell Research and Application (CiRA), Kyoto University, provides publicly available research-grade cell stocks including 29 human iPSC lines and 10 disease-specific iPSC lines.…”

pH-responsive antibodies for therapeutic applications

“…The unprecedented story of anti-CD3 Muromonab OKT3 clone [ 5 – 8 ] for immune modulation upon transplant and its approval by the Food and Drug Administration (FDA) has paved the way to success for several antibody-based therapeutics. To that extent, antibodies and antibody-based therapeutics have become one of the fastest-growing treatment modalities within the modern drug arsenal, with a projected revenue of 300B USD by 2025 [ 9 ]. As of March 2020, the FDA has approved over 90 antibodies, and several of them (> 10) are under review for a variety of disease indications.…”